AP
ARIA

AHL Partners’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

AHL Partners’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-20,701
Closed -$283K – 1302
2016
Q3 		$283K Buy
+20,701
New +$208K 0.01% 991

Other funds holding ARIA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

AHL Partners's ARIA Position: Q4 2016 in Review

AHL Partners sold out of Ariad Pharmaceuticals Inc (ARIA) in Q4 2016, closing a stake of 20,701 shares — an estimated $283K sold.

AHL Partners first reported a position in ARIA in Q3 2016 and held it in 1 quarter. The position peaked at $283K in Q3 2016. 200 funds tracked by Wall St. Rank hold ARIA as of Q4 2016.

  • AHL Partners reported no remaining Ariad Pharmaceuticals Inc position as of Q4 2016 after selling out during the quarter.
  • AHL Partners sold 20,701 Ariad Pharmaceuticals Inc shares in Q4 2016, an estimated $283K.
  • AHL Partners first reported a position in Ariad Pharmaceuticals Inc in Q3 2016 and held it in 1 quarter.
  • AHL Partners's Ariad Pharmaceuticals Inc position peaked at $283K in Q3 2016.
  • 200 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q4 2016.

Based on AHL Partners's 13F filing for Q4 2016, filed 14 Feb 2017.